CD274 and neoplasm: The effect was negligible in patients in the stage II–IIIA population whose tumors expressed PD-L1 on less than 1% of tumor cells based on a post-hoc exploratory analysis (unstratified HR 0.97; 95% CI 0.72–1.31) [113].